Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.70 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20551914 | 0.87 | KCNH2 (0.52) | KCNH2SCN5AKDM4EKMT2A | |
| SCHEMBL20549416 | 0.87 | KCNH2 (0.52) | KCNH2SCN5AKDM4EKMT2A | |
| SCHEMBL20549195 | 0.87 | KCNH2 (0.52) | KCNH2SCN5AKDM4E | |
| SCHEMBL20553335 | 0.87 | KCNH2 (0.52) | KCNH2SCN5AKDM4E | |
| SCHEMBL20549186 | 0.87 | KCNH2 (0.60) | KCNH2SCN5APIM1PIM3PIM2 | |
| SCHEMBL20549482 | 0.87 | KCNH2 (0.58) | KCNH2SCN5APIM1PIM3PIM2 | |
| SCHEMBL20551580 | 0.87 | KCNH2 (0.58) | KCNH2SCN5APIM1PIM3PIM2 | |
| SCHEMBL20549395 | 0.86 | KCNH2 (0.51) | KCNH2SCN5AKDM4E | |
| SCHEMBL20549401 | 0.85 | KCNH2 (0.50) | KCNH2SCN5AKDM4E | |
| SCHEMBL20549484 | 0.82 | KCNH2 (1.00) | KCNH2SCN5ACYP3A4KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | TOP1, TOP2A, TOP2B | KCNH2 2920/4885SCN5A 1467/4885PIM1 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.